{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin-to-skin&page=5", "query": { "condition": "Skin-to-skin", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 6423, "total_pages": 643, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin-to-skin&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin-to-skin&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T21:02:48.056Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05376878", "title": "An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Metastatic Breast Carcinoma", "Metastatic Malignant Neoplasm in the Brain" ], "interventions": [ { "name": "Copper Cu 64-DOTA-Trastuzumab", "type": "OTHER" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "DEVICE" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Trastuzumab Deruxtecan", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "PROCEDURE", "DEVICE", "BIOLOGICAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2022-12-21", "completion_date": "2027-04-27", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-10-09T21:02:48.056Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05376878" }, { "nct_id": "NCT03345485", "title": "Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Small Cell Lung Cancer", "Soft Tissue Sarcoma", "Triple-negative Breast Cancer", "Ovarian Cancer", "Endometrial Cancer" ], "interventions": [ { "name": "Tinostamustine 60mg/m2 over 30min", "type": "DRUG" }, { "name": "Tinostamustine 80mg/m2 over 30min", "type": "DRUG" }, { "name": "Tinostamustine 100mg/m2 over 30min", "type": "DRUG" }, { "name": "Tinostamustine 60mg/m2 over 60min", "type": "DRUG" }, { "name": "Tinostamustine 80mg/m2 over 60min", "type": "DRUG" }, { "name": "Tinostamustine 100mg/m2 over 60min", "type": "DRUG" }, { "name": "Tinostamustine 80mg/m2 over 80min", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mundipharma Research Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 71, "start_date": "2017-11-08", "completion_date": "2023-03-29", "has_results": true, "last_update_posted_date": "2024-10-21", "last_synced_at": "2026-10-09T21:02:48.056Z", "location_count": 5, "location_summary": "Los Angeles, California • Palo Alto, California • Ann Arbor, Michigan + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03345485" }, { "nct_id": "NCT05715125", "title": "VTX958 Versus Placebo for the Treatment of Active Psoriatic Arthritis (Tranquility-PsA)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Psoriatic Arthritis" ], "interventions": [ { "name": "Dose A VTX958", "type": "DRUG" }, { "name": "Dose B VTX958", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ventyx Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 205, "start_date": "2023-01-31", "completion_date": "2024-01-02", "has_results": false, "last_update_posted_date": "2024-12-27", "last_synced_at": "2026-10-09T21:02:48.056Z", "location_count": 15, "location_summary": "Phoenix, Arizona • Newport Beach, California • Clearwater, Florida + 12 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Newport Beach", "state": "California" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Miami Lakes", "state": "Florida" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT05715125" }, { "nct_id": "NCT01369589", "title": "An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Xerostomia", "Sjogren's Syndrome" ], "interventions": [ { "name": "P-552", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Parion Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2010-11", "completion_date": "2011-04", "has_results": false, "last_update_posted_date": "2019-04-23", "last_synced_at": "2026-10-09T21:02:48.056Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01369589" }, { "nct_id": "NCT06651476", "title": "A Randomized Controlled Trial to Test the Effects Oxytocin and Vibration Have on Heat Pain Threshold After UV-B Burn", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sunburn" ], "interventions": [ { "name": "oxytocin", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 38, "start_date": "2024-12-05", "completion_date": "2025-11-20", "has_results": false, "last_update_posted_date": "2026-01-12", "last_synced_at": "2026-10-09T21:02:48.056Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06651476" }, { "nct_id": "NCT03922308", "title": "Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acquired Thrombotic Thrombocytopenic Purpura (aTTP)" ], "interventions": [ { "name": "Placebo", "type": "OTHER" }, { "name": "SHP655", "type": "DRUG" }, { "name": "Standard of Care", "type": "OTHER" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 28, "start_date": "2019-10-09", "completion_date": "2021-08-05", "has_results": true, "last_update_posted_date": "2022-12-01", "last_synced_at": "2026-10-09T21:02:48.056Z", "location_count": 7, "location_summary": "Birmingham, Alabama • Boston, Massachusetts • Minneapolis, Minnesota + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03922308" }, { "nct_id": "NCT02460497", "title": "Minoxidil 2% Solution and Botanical Hair Regimen in Women With Thinning Hair and Female Pattern Hair Loss/Androgenic Alopecia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Female Pattern Hair Loss, Androgenic Alopecia" ], "interventions": [ { "name": "Treatment: Minoxidil 2% / Botanical Hair Solution for Women", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Galderma R&D", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "FEMALE", "summary": "18 Years to 60 Years · Female only" }, "enrollment_count": 61, "start_date": "2015-05-27", "completion_date": "2015-09-19", "has_results": true, "last_update_posted_date": "2023-08-01", "last_synced_at": "2026-10-09T21:02:48.056Z", "location_count": 1, "location_summary": "Richardson, Texas", "locations": [ { "city": "Richardson", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02460497" }, { "nct_id": "NCT05696626", "title": "Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Lasofoxifene in combination with abemaciclib", "type": "DRUG" }, { "name": "Fulvestrant in combination with abemaciclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "LeonaBio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 600, "start_date": "2023-10-31", "completion_date": "2028-04", "has_results": false, "last_update_posted_date": "2026-06-22", "last_synced_at": "2026-10-09T21:02:48.056Z", "location_count": 36, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Santa Rosa, California + 25 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05696626" }, { "nct_id": "NCT04752826", "title": "BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Malignancies", "Ovarian Cancer", "T-cell Lymphoma", "Melanoma" ], "interventions": [ { "name": "BI-1808", "type": "DRUG" }, { "name": "Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection", "type": "DRUG" }, { "name": "Paclitaxel 80 mg/m2 weekly", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioInvent International AB", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2021-01-25", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-09T21:02:48.056Z", "location_count": 3, "location_summary": "Duarte, California • New York, New York • Philadelphia, Pennsylvania", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04752826" }, { "nct_id": "NCT00091143", "title": "Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "gp100 antigen", "type": "BIOLOGICAL" }, { "name": "incomplete Freund's adjuvant", "type": "BIOLOGICAL" }, { "name": "keyhole limpet hemocyanin", "type": "BIOLOGICAL" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Providence Cancer Center, Earle A. Chiles Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2004-07", "completion_date": "2010-03", "has_results": false, "last_update_posted_date": "2013-04-04", "last_synced_at": "2026-10-09T21:02:48.056Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00091143" } ] }